Novel interactions between the 5-HT transporter, 5-HT 1B receptors and Rho kinase in vivo and in pulmonary fibroblasts

British Journal of Pharmacology

Volumn 155, Issue 4, 2008, Pages 606-616

  Mair, K M ^a   MacLean, M R ^a   Morecroft, I ^a   Dempsie, Y ^a   Palmer, T M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

5 HT; Fibroblast; Proliferation; Pulmonary arterial hypertension; Rho kinase

Indexed keywords

3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDIN 5 ONE; 3 (3 DIMETHYLAMINOPROPYL) 4 HYDROXY N [4 (4 PYRIDINYL)PHENYL]BENZAMIDE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; MITOGEN ACTIVATED PROTEIN KINASE; RHO KINASE; SEROTONIN 1B RECEPTOR; SEROTONIN TRANSPORTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HEART RIGHT VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; LUNG FIBROBLAST; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PULMONARY HYPERTENSION;

AMIDES; ANIMALS; ANOXIA; ANTIHYPERTENSIVE AGENTS; CELL PROLIFERATION; CRICETINAE; CRICETULUS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; HUMANS; HYPERTENSION, PULMONARY; MICE; MICE, INBRED C57BL; PULMONARY ARTERY; PYRIDINES; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT2A; RHO-ASSOCIATED KINASES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SIGNAL TRANSDUCTION;

EID: 53849083055     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.310     Document Type: Article

References (48)

1. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y et al. (2004). Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 94: 385-393.
2. Abe K, Tawara S, Oi K, Hizume T, Uwatoku T, Fukumoto Y et al. (2006). Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. J Cardiovasc Pharmacol 48: 280-285.
3. Aktories K, Wilde C, Vogelsgesang M (2004). Rho-modifying C3-like ADP-ribosyltransferases. Rev Physiol Biochem Pharmacol 152: 1-22.
4. Kip1 levels by distinct mechanisms. Mol Cell Biol 26: 4612-4627.
5. Dickinson RJ, Keyse SM (2006). Diverse physiological functions for dual-specificity MAP kinase phosphatases. J Cell Sci 119: 4607-4615.
6. Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M et al. (2000). Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 105: 1555-1562.
7. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F et al. (2001). Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108: 1141-1150.
8. Eddahibi S, Raffestin B, Pham I, Launay JM, Aegerter P, Sitbon M et al. (1997). Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Am J Physiol 41: H1173-H1181.
9. Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG et al. (2004). Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol 287: L656-L664.
10. Fukumoto Y, Tawara S, Shimokawa H (2007). Recent progress in the treatment of pulmonary arterial hypertension: expectation for Rho-kinase inhibitors. Tohoku J Exp Med 211: 309-320.
11. Gabbiani G (2003). The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 200: 500-503.
12. Guignabert C, Izikki M, Tu LI, Li ZL, Zadigue P, Barlier-Mur AM et al. (2006). Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 98: 1323-1330.
13. Guilluy C, Rolli-Derkinderen M, Tharaux PL, Melino G, Pacaud P, Loirand G (2007). Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells. J Biol Chem 282: 2918-2928.
14. Guilluy C, Sauzeau V, Rolli-Derkinderen M, Guerin P, Sagan C, Pacaud P et al. (2005). Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 146: 1010-1018.
15. Harrison RE, Flanagan JA, Sankelo M, Abdalla SA, Rowell J, Machado RD et al. (2003). Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 40: 865-871.
16. Homma N, Nagaoka T, Morio Y, Ota H, Gebb SA, Karoor V et al. (2007). Endothelin-1 and serotonin are involved in activation of RhoA/Rho kinase signaling in the chronically hypoxic hypertensive rat pulmonary circulation. J Cardiovasc Pharmacol 50: 697-702.
17. Hyvelin JM, Howell K, Nichol A, Costello CM, Preston RJ, McLoughlin P (2005). Inhibition of rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ Res 97: 185-191.
18. Im E, Kazlauskas A (2007). Src family kinases promote vessel stability by antagonizing the Rho/ROCK pathway. J Biol Chem 282: 29122-29129.
19. Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N et al. (2006). Beneficial acute effects of Rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 70: 174-178.
20. Jiang BH, Tawara S, Abe K, Takaki A, Fukumoto Y, Shimokawa H (2007). Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 49: 85-89.
21. Jin HG, Yamashita H, Nagano Y, Fukuba H, Hiji M, Ohtsuki T et al. (2006). Hypoxia-induced upregulation of endothelial small G protein RhoA and Rho-kinase/ROCK2 inhibits eNOS expression. Neurosci Lett 408: 62-67.
22. 1B/1D-receptor antagonist GR127935. Circ Res 89: 1231-1239.
23. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA, Loyd JE et al. (2000). Heterozygous germline mutations in BMPR2, encoding a TGF-b receptor, cause familial primary pulmonary hypertension. Nat Genet 26: 81-84.
24. Laudi S, Trump S, Schmitz V, West J, McMurtry IF, Mutlak H et al. (2007). Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am J Physiol Lung Cell Mol Physiol 293: L630-L638.
25. Lawrie A, Spiekerkoetter E, Martinez EC, Ambartsumian N, Sheward WJ, MacLean MR et al. (2005). Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ Res 97: 227-235.
26. Lee SL, Wang WW, Fanburg BL (1998). Superoxide as an intermediate signal for serotonin-induced mitogenesis. Free Radic Biol Med 24: 855-858.
27. Lee SL, Wang WW, Finlay GA, Fanburg BL (1999). Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion. Am J Physiol 277: L282-L291.
28. Liu YL, Fanburg BL (2006). Serotonin-induced growth of pulmonary artery smooth muscle requires activation of phosphatidylinositol 3-kinase/serine- threonine protein kinase B/mammalian target of rapamycin/p70 ribosomal S6 kinase 1. Am J Respir Cell Mol Biol 34: 182-191.
29. Liu YL, Suzuki YJ, Day RM, Fanburg BL (2004). Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res 95: 579-586.
30. Long L, MacLean MR, Jeffery TK, Morecroft I, Yang XD, Rudarakanchana N et al. (2006). Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 98: 818-827.
31. 1-like receptor-mediated vasoconstriction in human pulmonary artery. Br J Pharmacol 119: 277-282.
32. MacLean MR, Deuchar GA, Hicks MN, Morecroft I, Shen S, Sheward J et al. (2004). Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation 109: 2150-2155.
33. MacLean MR, Herve P, Eddahibi S, Adnot S (2000). 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 131: 161-168.
34. MacLean MR, Sweeney G, Baird M, McCulloch KM, Houslay M, Morecroft I (1996b). 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br J Pharmacol 119: 917-930.
35. McNamara PJ, Murthy P, Kantores C, Teixeira L, Engelberts D, van Vliet T et al. (2008). Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide. Am J Physiol Lung Cell Mol Physiol 294: L205-L213.
36. 1B receptor. Br J Pharmacol 128: 730-734.
37. Morecroft I, Loughlin L, Nilsen M, Colston J, Dempsie Y, Sheward J et al. (2005). Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries. J Pharmacol Exp Ther 313: 539-548.
38. Nagaoka T, Fagan KA, Gebb SA, Morris KG, Suzuki T, Shimokawa H et al. (2005). Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 171: 494-499.
39. Nagaoka T, Gebb SA, Karoor V, Homma N, Morris KG, McMurtry IF et al. (2006). Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat. J Appl Physiol 100: 996-1002.
40. Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S (1996). ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 392: 189-193.
41. Noma K, Oyama N, Liao JK (2006). Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 290: C661-C668.
42. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N et al. (2007). Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 100: 923-929.
43. Smith P, Heath D, Yacoub M, Madden B, Caslin A, Gosney J (1990). The ultrastructure of plexogenic pulmonary arteriopathy. J Pathol 160: 111-121.
44. Stenmark KR, Davie N, Frid M, Gerasimovskaya E, Das M (2006). Role of the adventitia in pulmonary vascular remodeling. Physiology 21: 134-145.
45. Walther DJ, Peter JU, Winter S, Holtje M, Paulmann N, Grohmann M et al. (2003). Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 115: 851-862.
46. Welsh DJ, Harnett M, Maclean M, Peacock AJ (2004). Proliferation and signaling in fibroblasts - role of 5-hydroxytryptamine(2A) receptor and transporter. Am J Respir Crit Care Med 170: 252-259.
47. Willers ED, Newman JH, Loyd JE, Robbins IM, Wheeler LA, Prince MA et al. (2006). Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 173: 798-802.
48. Yi ES, Kim H, Ahn H, Strother J, Morris T, Masliah E et al. (2000). Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med 162: 1577-1586.